Stop Use of Ivermectin for COVID-19: AMA, Pharmacist Groups

THURSDAY, Sept. 2, 2021 (HealthDay News) -- The prescribing, dispensing, and use of ivermectin to prevent or treat COVID-19 outside of clinical trials must end immediately, the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists say.
The drug has U.S. Food and Drug Administration approval to treat people with infections caused by internal and external parasites but is not approved to prevent or treat COVID-19. Ivermectin is also available for veterinary use in horses and other animals, but medications intended for animals should not be used by humans.
"We are alarmed by reports that outpatient prescribing for and dispensing of ivermectin have increased 24-fold since before the pandemic and increased exponentially over the past few months," the groups said in a statement. They noted that calls to poison control centers related to ivermectin have increased fivefold compared with before the pandemic.
No form of ivermectin has been approved to treat or prevent COVID-19, the FDA emphasized. It said it was compelled to issue a warning due to "a lot of misinformation" around the drug, according to the update.
The U.S. Centers for Disease Control and Prevention also issued an advisory saying ivermectin is not authorized or approved for the prevention or treatment of COVID-19. The CDC has warned about the potentially toxic effects of the drug, including "nausea, vomiting and diarrhea. Overdoses are associated with hypotension and neurologic effects such as decreased consciousness, confusion, hallucinations, seizures, coma, and death."
Related Posts
Los hombres negros tienen menos probabilidades de recibir la vacuna contra la viruela del simio
LUNES, 29 de agosto de 2022 (HealthDay News) -- Aunque ahora hay suficiente...
¿Es Eczema o Psoriasis? Un Experto Ofrece Consejo
VIERNES, 8 de septiembre de 2023 (Noticias de HealthDay) - El eczema y la...
Health Highlights: Jan. 31, 2022
Scientists say new 'stealth' Omicron variant poses little threat.The variant,...
Female Surgeons Have Lower Rates of Adverse Postoperative Outcomes
FRIDAY, Sept. 1, 2023 (HealthDay News) -- Patients treated by female surgeons...